We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

54 hedge funds and large institutions have $87.3M invested in Enanta Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 17 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 6

43% more capital invested

Capital invested by funds: $60.9M → $87.3M (+$26.4M)

31% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 13

29% more funds holding

Funds holding: 42 → 54 (+12)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
54
Holders Change
+12
Holders Change %
+28.57%
% of All Funds
1.75%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
18
Increased
17
Reduced
13
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$10.9M
2
B
Bailard
California
+$2.49M
3
SCM
Sigma Capital Management
Connecticut
+$1.53M
4
BIM
Bogle Investment Management
Massachusetts
+$1.03M
5
Franklin Resources
Franklin Resources
California
+$971K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$7.72M
2
BI
BVF Inc
California
-$2.72M
3
BIT
BlackRock Institutional Trust
California
-$1.94M
4
BA
BlackRock Advisors
Delaware
-$803K
5
Morgan Stanley
Morgan Stanley
New York
-$773K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$401K +$323K +16,906 New
Wells Fargo
27
Wells Fargo
California
$398K +$332K +17,368 New
Deutsche Bank
28
Deutsche Bank
Germany
$396K +$9.97K +522 +3%
TCIM
29
TIAA CREF Investment Management
New York
$340K +$8.85K +463 +3%
PAM
30
Panagora Asset Management
Massachusetts
$310K -$180K -9,426 -41%
NSEDCP
31
NJ State Employees Deferred Compensation Plan
New Jersey
$287K – – –
NFA
32
Nationwide Fund Advisors
Ohio
$246K +$183K +9,575 +838%
TAM
33
Tocqueville Asset Management
New York
$241K +$201K +10,500 New
BIM
34
BlackRock Investment Management
Delaware
$232K +$19.8K +1,035 +11%
SO
35
STRS Ohio
Ohio
$222K +$153K +8,000 +471%
Goldman Sachs
36
Goldman Sachs
New York
$220K -$78.2K -4,093 -30%
LOM
37
Loeb Offshore Management
New York
$209K +$174K +9,104 New
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$150K +$3.82K +200 +3%
CCMH
39
Cornerstone Capital Management Holdings
New York
$119K +$99.4K +5,200 New
TA
40
Teachers Advisors
New York
$105K -$535 -28 -0.6%
U
41
UBS
Switzerland
$84K +$48.6K +2,542 +228%
SCA
42
SAC Capital Advisors
Connecticut
$57K +$47.8K +2,500 New
SGAM
43
Smith Group Asset Management
Texas
$56K +$47K +2,457 New
AIG
44
American International Group
New York
$55.9K +$46.6K +2,440 New
TRCT
45
Tower Research Capital (TRC)
New York
$53K -$87.5K -4,580 -66%
BA
46
BlackRock Advisors
Delaware
$45K -$803K -42,025 -96%
BG
47
BlackRock Group
United Kingdom
$32K +$26.4K +1,382 New
GPGA
48
Grandeur Peak Global Advisors
Utah
$29K +$18.2K +950 +317%
GT
49
Glenmede Trust
Pennsylvania
$22K – – –
AllianceBernstein
50
AllianceBernstein
Tennessee
$13K -$14.8K -776 -57%
1
2
3

ENTA Hedge Fund Activity: Q3 2013 in Review

54 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2013, worth a combined $87.3M — up 43% from $60.9M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ENTA positions and 6 closed out — a net gain of 12 holders — while 17 added to existing stakes and 13 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $10.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $7.72M sold.

  • 54 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2013, up from 42 in Q2 2013.
  • Funds reported $87.3M of Enanta Pharmaceuticals stock for Q3 2013, up 43% quarter-over-quarter.
  • 18 funds opened new Enanta Pharmaceuticals positions in Q3 2013 and 6 closed out, a net change of +12 holders.
  • The largest Enanta Pharmaceuticals buyer in Q3 2013 was Consonance Capital Management, an estimated $10.9M added.
  • The largest Enanta Pharmaceuticals seller in Q3 2013 was RA Capital Management, an estimated $7.72M sold.

Based on aggregated 13F filings for Q3 2013.